Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01446016 · ClinicalTrials.gov registry record · Phase 2
Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01446016 is a Phase 2 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 38 participants.
The verdict
NCT01446016, a Phase 2 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therapy. The investigators want to see the response of breast cancer cell when treated with Chloroquine used in combination with chemotherapy. Chemotherapy is an anti-cancer drug that is given through your vein. The chemotherapy used in this study is either Taxane (Paclitaxel) or Taxane-like drugs (Abraxane, Ixabepilone or Docetaxel).
Interventions
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Abraxane
- DRUG Ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-09 |
| Est. Completion | 2019-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01446016
The ClinicalTrials.gov registry entry for NCT01446016 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT01446016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01446016 about?
NCT01446016 is a clinical study titled "Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)". The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therapy. The investigators want to see the response of breas...
What is the current status of trial NCT01446016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2011-09. Estimated completion is 2019-03-01.
What interventions are being tested in trial NCT01446016?
The interventions under investigation include: Docetaxel (DRUG), Paclitaxel (DRUG), Abraxane (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT01446016?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.